Real-World Comparison of Tirzepatide and Semaglutide in Patients with Type 2 Diabetes

A Retrospective Comparative Cohort Study of Tirzepatide and Semaglutide in Real-World Clinical Practice in Patients with Type 2 Diabetes - TIRASEMA Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061320

Enrollment

200

Registered

2026-05-01

Start date

2026-04-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes who were receiving treatment during the study period, were considered by the treating physician to be appropriate candidates for treatment with semaglutide or tirzepatide, and provided written informed consent for study participation.

Exclusion criteria

Exclusion criteria: Patients from whom written informed consent for study participation could not be obtained

Design outcomes

Primary

Measure	Time frame
The primary outcomes are the changes from baseline to 6 months after treatment initiation in the Eating Behavior Questionnaire (EBQ) score and the Diabetes Treatment Satisfaction Questionnaire (DTSQ) score.	—

Countries

Japan

Contacts

Public ContactYasutaka Suzuki

Kimitsu Chuo Hospital Department of Medicine, Division of Diabetes, Endocrinology and Metabolism

ishibashi-cib@umin.net0438-36-1071

Outcome results